Tiziana Life Sciences CEO buys 321K shares

Tiziana Life Sciences Ltd reports that Chief Executive Officer Ivor Elrifi purchased 321,423 common shares on Nasdaq at $1.00 per share, increasing his holdings to 4,793,684 shares.

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd reports that Chief Executive Officer Ivor Elrifi purchased 321,423 common shares on Nasdaq at $1.00 per share, increasing his holdings to 4,793,684 shares.

The company also highlights its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody being developed for neuroinflammatory and neurodegenerative diseases. Fourteen patients with non-active secondary progressive multiple sclerosis have received intranasal foralumab in an open-label Expanded Access Program, with either improvement or stability of disease observed within six months in all patients. Intranasal foralumab is additionally being studied in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in the same indication.

Filing Explained

As a Form 6-K, this is an interim report furnishing the CEO’s share-purchase announcement; the company states the attached release is not deemed filed under Section 18 or incorporated by reference into other filings.

Key Figures

CEO share purchase: 321,423 shares Purchase price: $1.00 per share CEO total holdings: 4,793,684 shares +3 more

6 metrics

CEO share purchase 321,423 shares Common shares purchased on Nasdaq by the CEO at $1.00 per share

Purchase price $1.00 per share Price per common share paid by CEO Ivor Elrifi

CEO total holdings 4,793,684 shares Total common shares held by the CEO after the reported purchase

Expanded Access patients 14 patients Number of na-SPMS patients dosed with intranasal foralumab in an Expanded Access Program

Observation period 6 months Period within which improvement or stability was seen in all Expanded Access patients

Clinical trial phase Phase 2a Stage of the randomized, double-blind trial of intranasal foralumab in na-SPMS

Key Terms

Expanded Access (EA) Program, Phase 2a, double-blind, monoclonal antibody, +1 more

5 terms

Expanded Access (EA) Program medical

"dosed in an open-label intermediate sized Expanded Access (EA) Program"

Phase 2a medical

"currently being studied in a Phase 2a, randomized, double-blind"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

double-blind medical

"Phase 2a, randomized, double-blind, placebo-controlled, multicenter"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

monoclonal antibody medical

"foralumab, a fully human, anti-CD3 monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

immunomodulation therapies medical

"a biotechnology company developing breakthrough immunomodulation therapies"

Treatments that change how the immune system behaves to prevent or fight disease, either by calming an overactive response or boosting a weak one — like adjusting a thermostat to keep temperature in a safe range. They matter to investors because they can create big market opportunities if proven effective, but also carry high development, clinical trial and regulatory risks that can strongly affect a company’s future value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What CEO share purchase did Tiziana Life Sciences (TLSA) report?

Tiziana Life Sciences reported that CEO Ivor Elrifi bought 321,423 common shares on Nasdaq at $1.00 per share, increasing his total holdings to 4,793,684 shares. This transaction reflects an additional open-market investment by the company’s chief executive.

What is the CEO’s total ownership in Tiziana Life Sciences (TLSA) after the purchase?

Following the reported transaction, CEO Ivor Elrifi holds 4,793,684 common shares of Tiziana Life Sciences. This figure includes the newly acquired 321,423 shares purchased on Nasdaq at $1.00 per share, as disclosed by the company.

What is foralumab, Tiziana Life Sciences’ (TLSA) lead development candidate?

Foralumab is described as a fully human anti-CD3 monoclonal antibody administered intranasally. It is being developed as an immunomodulation therapy and is noted as the only fully human anti-CD3 mAb currently in clinical development, targeting neuroinflammatory and neurodegenerative diseases.

How many patients have received intranasal foralumab in Tiziana Life Sciences’ (TLSA) Expanded Access Program?

Tiziana Life Sciences states that 14 patients with non-active secondary progressive multiple sclerosis have been dosed with intranasal foralumab in an open-label, intermediate-sized Expanded Access Program, with improvement or stability observed within 6 months in all patients.

What clinical trial is evaluating intranasal foralumab for Tiziana Life Sciences (TLSA)?

Intranasal foralumab is being studied in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis, according to Tiziana Life Sciences’ description of its development programs.

What therapeutic approach is Tiziana Life Sciences (TLSA) focusing on?

Tiziana Life Sciences focuses on immunomodulation therapies using transformational drug delivery technologies, notably intranasal delivery. The company highlights intranasal foralumab as its lead candidate and notes that this approach is intended to offer alternative routes of immunotherapy with potential safety and tolerability advantages.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 07:00 AM Accepted by SEC EDGAR 08/06/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

August 2026

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 6, 2026, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 321,423 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,793,684 common shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: August 6, 2026	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated August 6, 2026

3

Exhibit 99.1

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

BOSTON, MA, August 6, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 321,423 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,793,684 common shares.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd

Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED AUGUST 6, 2026 6.1 KB